Kos Biotechnology Partners, a life sciences investment firm, has announced the third closing of its inaugural global fund, totaling $123 million in capital commitments. This fund, notable for being Greece’s first life sciences-dedicated investment vehicle and the largest venture capital fund launch in the country’s history, aims to bridge the US biopharma ecosystem with Europe’s. The firm, co-founded by Dr. Simos Simeonidis and Alex Tzoukas, focuses on high-impact investments in biotech, pharma services, and tech-enabled technologies, currently advancing its strategy with investments in innovative companies such as tech-enabled pharma services provider Epikast.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-third-closing-of-global-life-sciences-fund-at-123-million-302799624.html
